Sugi Predict

Sugi Predict / Compounds / SCHEMBL4863136

SCHEMBL4863136

SCHEMBL4863136

COc1ccc(-c2c(C)n[nH]c2N)cc1OC

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.64
▸ ALDH1A1 P00352 4/20 0.64
▸ HSD17B10 Q99714 3/20 0.54
▸ LMNA P02545 2/20 0.50
▸ POLB P06746 1/20 0.50
▸ MAPT P10636 3/20 0.49
▸ MAPK1 P28482 2/20 0.49
▸ TSHR P16473 1/20 0.49
▸ ALOX12 P18054 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ ACHE P22303 3/20 0.48
▸ APP P05067 1/20 0.47
▸ BCHE P06276 1/20 0.47
▸ GSK3B P49841 1/20 0.47
▸ PDE4A P27815 2/20 0.47
▸ PDE4B Q07343 2/20 0.47
▸ PDE4C Q08493 2/20 0.47
▸ PDE4D Q08499 2/20 0.47
▸ KMT2A Q03164 2/20 0.45
▸ MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1056955 0.80 KDM4E (0.43) KDM4EALDH1A1HSD17B10LMNAPOLB
SCHEMBL15452462 0.80 ACHE (0.56) KDM4EALDH1A1HSD17B10LMNAPOLB
SCHEMBL4711533 0.79 KDM4E (0.57) KDM4EALDH1A1HSD17B10LMNAMAPT
SCHEMBL13516427 0.79 MAPT (0.50) KDM4EALDH1A1HSD17B10POLBMAPT
SCHEMBL5730488 0.76 ALDH1A1 (0.57) KDM4EALDH1A1HSD17B10LMNAMAPT
SCHEMBL14350130 0.75 GAA (0.45) KDM4EALDH1A1HSD17B10MAPTMAPK1
SCHEMBL842957 0.74 SMN1; SMN2 (0.47) KDM4EALDH1A1HSD17B10LMNAPOLB
SCHEMBL15742048 0.74 IKBKB (0.62) KDM4EALDH1A1MAPTKMT2A
SCHEMBL21334260 0.74 KDM4E (0.48) KDM4EALDH1A1HSD17B10LMNAPOLB
SCHEMBL26414604 0.73 KDM4E (0.57) KDM4EALDH1A1HSD17B10LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3096762-B1 PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL COMPOUNDS CUROVIR AB (SE) 2023-06-28 — — EP disclosed
EP-3313842-B1 PYRAZOLO[1,5-A]TRIAZIN-4-AMINE DERIVATIVES USEFUL IN THERAPY CUROVIR AB (SE) 2020-04-15 — — EP disclosed
US-10407429-B2 Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy CUROVIR AB (SE) 2019-09-10 — — US disclosed
US-20180298009-A1 Fused Pyrazole Derivatives As Kinase Inhibitors UCB BIOPHARMA SPRL (BE) 2018-10-18 — — US disclosed
EP-3356367-A1 FUSED PYRAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Biopharma SPRL (BE) 2018-08-08 — — EP disclosed
US-9963455-B2 Pyrazolo[1,5-a]pyrimidines as antiviral compounds CUROVIR AB (SE) 2018-05-08 — — US disclosed
US-9963455-B2 Pyrazolo[1,5-a]pyrimidines as antiviral compounds CUROVIR AB (SE) 2018-05-08 — — US disclosed
US-20160318937-A1 PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL COMPOUNDS CUROVIR AB (SE) 2016-11-03 — — US disclosed
US-20160318937-A1 PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL COMPOUNDS CUROVIR AB (SE) 2016-11-03 — — US disclosed
WO-2015110491-A2 PYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE DERIVATIVES USEFUL IN THERAPY APODEMUS AB (SE) 2015-07-30 — — WO disclosed
US-7393870-B2 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2008-07-01 — — US disclosed
US-20060074116-A1 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-04-06 — — US disclosed
US-7005444-B2 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-02-28 — — US disclosed
US-20030130328-A1 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-07-10 — — US disclosed
US-6559173-B1 organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. ALLERGAN, INC. 2003-05-06 — — US disclosed
WO-2003026650-A1 3-(HETEROARYLAMINO)METHYLENE-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN, INC. (US) 2003-04-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318937-A1 PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL COMPOUNDS TYMP, ZC3HAV1, TYMS KDM4E 3727/4885ALDH1A1 586/4885HSD17B10 3920/4885
US-10407429-B2 Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy NAT1, TPMT, THPO KDM4E 3279/4885ALDH1A1 635/4885HSD17B10 3515/4885
US-20180298009-A1 Fused Pyrazole Derivatives As Kinase Inhibitors PI4KA, PI4K2B, PI4KB KDM4E 1098/4885ALDH1A1 3654/4885HSD17B10 2839/4885
US-20060074116-A1 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 KDM4E 1221/4885ALDH1A1 2360/4885HSD17B10 3354/4885
US-20030130328-A1 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 KDM4E 1221/4885ALDH1A1 2360/4885HSD17B10 3354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.